---
title: "Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | APVO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285373727.md"
description: "Aptevo has reported an 87% clinical benefit and 81% remission rate in 31 evaluable frontline AML patients through Cohort 5, significantly outperforming benchmarks. The RAINIER study is on track for completion in 2026, with plans for Phase 2 dose selection."
datetime: "2026-05-06T04:05:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285373727.md)
  - [en](https://longbridge.com/en/news/285373727.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285373727.md)
generator: "portal-rs"
---

# Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | APVO Stock News

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | APVO Stock News

### Related Stocks

- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [09:28 ETNew LabCentral Program "The Loop" Offers International Biotech Start-Ups and Partner Organizations Curated Learnings Directly from U.S. Market](https://longbridge.com/en/news/298328140.md)
- [Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results | APVO Stock News](https://longbridge.com/en/news/295932565.md)
- [Aptevo Therapeutics announces special shareholder meeting](https://longbridge.com/en/news/297564634.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**